Rossi C, André M, Dupuis J, Morschhauser F, Joly B, Lazarovici J, Ghesquières H, Stamatoullas A, Nicolas-Virelizier E, Feugier P, Gac A-C, Moatti H, Fornecker L-M, Deau B, Joubert C, Fortpied C, Raemaekers J, Federico M, Kanoun S, Meignan M, Traverse-Glehen A, Cottereau A-S, Casasnova R-O. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline. haematol [Internet]. 2022Dec.1 [cited 2024Apr.26];107(12):2897-904. Available from: https://haematologica.org/article/view/haematol.2021.280004